Biodelivery Sciences International, Inc.

Avior, Inc.

Niraj Vasisht

Andrew Finn

Karl Dewayne Kelly

Samarth Vasisht

A pharmaceutical active-containing transmucosal delivery device comprises a polymer film comprising a polymer matrix, wherein the film has a pH in the range of about 4 to about 9, and a pharmaceutical active composition disposed on a surface of the polymer film. The composition comprises at least one pharmaceutical active ingredient in the form of particles, and wherein the particles have an average particle size of about 100 nm to about 5 microns, an anti-crystallization agent, and a pH adjusting agent, wherein the concentration of the pharmaceutical active ingredient is at least 20% w/w relative to the total weight of the pharmaceutical active composition. The delivery device exhibits a residence time in the mouth of a subject ranging from about 5 minutes to about 30 minutes and is substantially mucoadhesive to a mucosa surface when placed sublingually under the tongue or placed buccally at the inner lining of the cheek.

Transmucosal film composition and methods of making and using the same

A transmucosal delivery device comprises a polymer film comprising a polymer matrix, and a pharmaceutical composition disposed on a surface of the polymer film, the composition comprising at least one pharmaceutical active, a binding polymer, a surfactant, a solubilizing solvent, and an anti-crystallization agent, wherein a dry concentration of the pharmaceutical active is greater than 10 wt % and the composition has a pH in a range of about 4 to about 8. The delivery device exhibits a residence time in the mouth of a subject ranging from about 5 minutes to about 15 minutes and is substantially mucoadhesive to a mucosal surface when placed sublingually under the tongue or placed buccally at the inner lining of the cheek of the subject.

Pharmaceutical active-containing film delivery device for oral transmucosal administration

Provided herein are methods for treating chronic pain by administering low doses of buprenorphine twice daily (or once daily) via a transmucosal drug delivery device. The methods and devices efficiently treat chronic pain without significant side effects.

Transmucosal drug delivery devices for use in chronic pain relief

The present invention provides methods for enhancing transmucosal uptake of a medicament, e.g., fentanyl or buprenorphine, to a subject and related devices. The method includes administering to a subject a transmucosal drug delivery device comprising the medicament. Also provided are devices suitable for transmucosal administration of a medicament to a subject and methods of their administration and use. The devices include a medicament disposed in a mucoadhesive polymeric diffusion environment and a barrier environment.

Transmucosal delivery devices with enhanced uptake

The present invention relates to a solid pharmaceutical dosage form for abusable drug delivery with reduced illicit abuse potential. The dosage form is presented as a bioerodable transmucosal delivery device that includes an abusable drug and an antagonist to the abusable drug associated with an abuse-resistant matrix. The devices of the invention may be in the form of a layered film or a tablet. Upon application in a non-abusive manner, the device adheres to the mucosal surface, providing transmucosal drug delivery of the drug with minimal absorption of the antagonist into systemic circulation.

Abuse resistant transmucosal drug delivery device

The present invention provides abuse deterrent mucoadhesive devices for delivery of buprenorphine. Each device comprises a mucoadhesive layer and a backing layer, and the pH in each layer is selected, such that absorption of buprenorphine is maximized.

Growing community of inventors

Cary, NC, United States of America

Niraj Vasisht